medigraphic.com
ISSN 1561-3186 (Electronic)

2015, Number 1

<< Back Next >>

Rev Acta Médica 2015; 16 (1)

Resistencia a la Insulina y Síndrome Metabólico en pacientes dislipidémicos

Calderín BRO, Yanes QMÁ, Yanes QM, Cabrera RE, Fernández-Britto RJE, Jiménez PR

Language: Spanish
References: 49
Page:
PDF size: 388.78 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Calderín Bouza RO, Orlandi González N. Síndrome Metabólico vs Síndrome de Insulinorresistencia. Diferentes términos, clasificaciones y enfoques: ¿existe o no? Rev Cubana Endocrinol. 2006;17(3):1-9.

  2. Calderín Bouza RO, Prieto Fernández M, Cabrea Rode E. Síndrome de Insulinorresistencia en niños y adolescentes. Rev Cubana Endocrinol. 2007;18(2):1-14.

  3. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Síndrome: mediators, antecedents and measurement. Diabetes Care. 2006;29(7):1700-6.

  4. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006;83(6):1237-47.

  5. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

  6. Himsworth HP. The mechanism of diabetes mellitus III. Human diabetes mellitus. Lancet 1939;2:171-5.

  7. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 2005 Dec;47(4):201-10.

  8. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Sindrome: Atherothrombosis disease. Diabetes Care 2006;29(8):1973-80.

  9. Bloomgarden ZT. Cardiovascular disease. Diabetes Care 2006;29(5):1160-1166.

  10. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: associated conditions. Diabetes Care. 2006;29(9):2165-74.

  11. Ochoa Montes LA, Yong Medina CA, Calderín Bouza RO, González Lugo M, Miguélez Nodarse R, Vilches Izquierdo E, Díaz Londres H. Factores de riesgo del síndrome metabólico en la muerte súbita cardíaca. Revista Cubana de Medicina. 2011;50(4):1-12.

  12. Fernández-Bergés D, Cabrera de León A, Sanz H, Elosua R, Guembe MJ, Alzamora M, et al. Síndrome metabólico en España: prevalencia y riesgo coronario asociado a la definición armonizada y a la propuesta por la OMS. Estudio DARIOS. Rev Esp Cardiol. 2012;65:241-86.

  13. Rydín L, Standl E, Barnitk M, Van den Beghe G, Betteridge J, et al. Guías de práctica clínica sobre diabetes, pre-diabetes y enfermedades cardiovasculares. Rev Esp Cardiol. 2007;60(5):525.e1-e64.

  14. Calderín Bouza, Raúl Orlando, Yanes Quesada M, Yanes Quesada MA, Adalys Rodríguez M, Prieto Valdés M, Carrasco Martínez B, Hernández Yero A. Síndrome metabólico y prediabetes. Rev Cubana de Endocrinol. 2011;22(1):1-7.

  15. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA,Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun;9(3):237-52.

  16. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26(3):575-81.

  17. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.

  18. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am. 2004;33(2):333-50.

  19. Blommgarden ZT. 2nd International Symposium on Triglycerides and HDL: Metabolic Syndrome. Diabetes Care. 2005;28(10):2577-2584.

  20. Blommgarden ZT. 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment. Diabetes Care. 2005;28(11):2795-802.

  21. Nasiff Hadad A, Pérez Pérez LM, Dueñas Herrera A, Espinosa Brito A, Herrera González A, Vázquez Vigoa A, Calderín Bouza RO, et al. Primer Consenso Nacional de Dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol. Suplemento de Endocrinología 2006;17(4):1-31.

  22. Isomaa B, Almgrem P, Tuomi T, Forsén B, Lhati K, Nissén M, Taskinen M, Groop L. Cardiovascular morbility and mortality associated with the Metabolic Syndrome, Diabetes Care 2001;24:683-9.

  23. Nassif Hadad A. Claro López, Espinosa Oliva R, Síndrome X en pacientes dislipidémicos, Rev Clínica Invest. Ateroesclerosis 1997;4(9):143-450.

  24. Calderín Bouza RO, Yanes Quesada MA, Márquez Pérez I, Senra Piedra G, Denis de Armas R, Infante Amorós A, Argüelles Zayas AC, Orlandi González N, Yanes Quesada M, Albert Cabrera M. Síndrome metabólico en familiares de primer grado de pacientes con diabetes Mellitus tipo 2. Rev Cubana Endocrinol. 2005 Sep.-Dic;16(3):1-16.

  25. Vázquez Vigoa A, Vázquez Cruz A, Calderín RO, Buchaca EF. Cruz Álvarez NM, Jiménez Paneque R, Luño J. Síndrome metabólico en pacientes hipertensos escenciales. Nefrología. 2003;23(5):423-31.

  26. Cabrera-Rode E, Orlandi N, Padrón Y, Arranz C, Olano R, Mayra Machado, Hernández-Yero A, Calderín R, Domínguez E. The effect of Diamel on patients with metabolic syndrome: a randomised, double-blinded, placebo-controlled study. J Diabetes. Accepted manuscript online: SEP 2012 05:30AM EST | doi: 10.1111/1753-0407.12007.

  27. American Diabetes Association. Position Statement. Standards of Medical Care in Diabetes. Diabetes Care. 2014;37(1):s14-s80.

  28. Chobanian AV, Bakies GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressures The JNC 7 Report. JAMA. 2003;289:2580.

  29. Marcuello C, Calle-Pascual AL, Fuentes M, Runkle I, Rubio MA, Montañez C, et al. Prevalence of the metabolic syndrome in Spain using regional cutoff points for waist circumference: the di@bet.es study. Acta Diabetol. 2013;50:615-23.

  30. Bellanger TM, Bray GA. Obesity related morbidity and mortality. J La State Med Soc. 2005 Jan; 157 Spec No 1:S42-9.

  31. Guallar-Castillón P, Francisco Pérez R, López García E, León-Muñoz LM, Aguilera MT, Graciani A, Gutiérrez-Fisac JR, Banegas JR y Rodríguez-Artalejo F. Magnitud y manejo del síndrome metabólico en España en 2008-2010: Estudio ENRICA. Rev Esp Cardiol. 2014. http://dx.doi.org/10.1016/j.recesp.2013.08.014

  32. Bray AG. Medical therapy for Obesity-Current Status and Future Hopes. Med Clin N Am. 2007;91:1225-53.

  33. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). Executive summary of the third report of the national cholesterol education program (NCEP). JAMA. 2001;285(19):2486-96.

  34. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol. 2012;49:89-95.

  35. Ebinc H, Ebinc FA, Ozkurt ZN, Dogru T, Yilmaz M. Relationship of left ventricular mass to insulin sensitivity and body mass index in healthy individuals. Acta Cardiol. 2006;61(4):398-405.

  36. Hernandez del Rey R, Armario P, Martin-Baranera M, Castellanos P. Clustering of cardiovascular risk factors and prevalence of metabolic syndrome in subjects with resistant hypertension Med Clin (Barc). 2006;127(7):241-5.

  37. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, Vaudo G, Mannarino E. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006;47(5):881-6.

  38. Palmieri V, Bella JN. Metabolic syndrome and left ventricular structure and functional abnormalities. Am J Hypertens. 2006;19(2):199-205.

  39. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-32.

  40. Brietske SA. Controversyin diagnosis and Management of the Metabolic Syndrome. Med Clin N Am. 2007;91:1041-61.

  41. Lann D, LeRoith D. Insulin Resistance as the Underlying Cause for the Metabolic Syndrome. Med Clin N Am. 2007;91:1063-77.

  42. Bloomgarden ZT. Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care. 2005;28(9):2312-9.

  43. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of obesity. Circulation 2009;120:1640-5.

  44. Mericq V.Prematurity and insulin sensitivity. Horm Res. 2006;65(3):131-6.

  45. Ong KK. Size at birth, postnatal growth and risk of obesity. Horm Res. 2006;65(3):65-9.

  46. Guallar-Castillón P, Francisco Pérez R, López García E, León-Muñoz LM, Aguilera MT, Graciani A , Gutiérrez-Fisac JR, Banegas JR y Rodríguez-Artalejo F. Magnitud y manejo del síndrome metabólico en España en 2008-2010: Estudio ENRICA. Rev Esp Cardiol. 2014. http://dx.doi.org/10.1016/j.recesp.2013.08.014

  47. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005 Mar;34(1):49-62.

  48. Bonora E, Kiecchl, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes 1998;1643-9.

  49. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical evaluation of adult treatment panel III criteria in identifying insulin Resistance with Dyslipidemia. Diabetes Care, 2004;27(4):978-83.




2020     |     www.medigraphic.com